This review investigated effectiveness of statins for treatment of sepsis. The authors concluded that statins had a beneficial effect on the outcome of infection, but could not make firm conclusions due to the poor quality of available data. This was an appropriate conclusion and is likely to be reliable.
Results of the review
Twenty-two studies (n=177,260) were included: one randomised controlled trial (RCT); seven prospective cohort studies; 12 retrospective cohort studies; and two retrospective case-control studies. The sample size ranged from 53 to 69,168 patients. Approximately two thirds of the studies reported a statistically significant benefit with statin use.
Patients with sepsis or at risk of sepsis (nine studies): In one RCT there was no statistically significant difference between pravastatin and placebo in incidence of sepsis in patients with subarachnoid haemorrhage, although there was a reduction in sepsis-related mortality in the statin group (6.25% in the statin group versus 71.43% in the placebo group, p<0.001). Three cohort studies that used propensity-matched sub-cohorts reported a statistically significant association between use of statins and reduced sepsis-related hospitalisations and infection-related mortality. Two of five non-
